SEARCH:   Advanced

Blood, 5 March 2009, Vol. 113, No. 10, pp. 2265-2274. Prepublished online as a Blood First Edition Paper on January 8, 2009; DOI 10.1182/blood-2008-06-160416. This Article Full Text (PDF) All Versions of this Article: blood-2008-06-160416v1 113/10/2265    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sauer, S. Articles by Menssen, H. D. Search for Related Content PubMed PubMed Citation Articles by Sauer, S. Articles by Menssen, H. D. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 2, 2008 Accepted December 11, 2008 Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Stefanie Sauer, Paola A. Erba, Mario Petrini, Andreas Menrad, Leonardo Giovannoni, Chiara Grana, Burkhard Hirsch, Luciano Zardi, Giovanni Paganelli, Giuliano Mariani, Dario Neri, Horst Durkop, and Hans D. Menssen* Department of Pathology, Campus Benjamin Franklin, Charite-Universitatsmedizin, Berlin, Germany Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy Department of Hematology, University of Pisa Medical School, Pisa, Italy Genzyme Europe Research, Cambridge Science Park, Cambridge, United Kingdom Philogen, SpA, Siena, Italy Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy Laboratory of Innovative Therapies, Centro Biotecnologie Avanzate, Genoa, Italy Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland Department of Global Clinical Development Oncology, Bayer HealthCare Pharmaceuticals, Montville, NJ, United States * Corresponding author; email: hansdietrich.menssen{at}bayer.com. Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. Being expressed in newly formed blood vessels of solid cancers but not in normal mature tissues, the extra-domain B of fibronectin (ED-B FN) is a promising target for selective cancer therapies. Using immunohistology with a new epitope retrieval technique for paraffin-embedded tissues, ED-B FN expression was found in biopsies from more than 200 Hodgkin and Non-Hodgkin lymphoma patients of nearly all entities, and in patients with myeloproliferative diseases. ED-B FN expression was nearly absent in normal lymph nodes (n=10) and bone marrow biopsies (n=9). The extent of vascular ED-B FN expression in lymphoma tissues was positively correlated with grade of malignancy. ED-B FN expression was enhanced in lymph nodes with severe lymphadenopathy and in some hyperplastic tonsils. The in vivo accessibility of ED-B FN was confirmed in three lymphoma patients, in whom the lymphoma lesions were visualized on scintigraphy with 131I-labeled L19 small immunoprotein (131I-L19SIP). In two relapsed Hodgkin lymphoma patients, 131I-L19SIP radioimmunotherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma therapies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: There will be blood: targeting tumor vasculature Nathan Fowler and Anas Younes Blood 2009 113: 2121-2122. [Full Text] [PDF] This article has been cited by other articles: E. Ventura, F. Sassi, S. Fossati, A. Parodi, W. Blalock, E. Balza, P. Castellani, L. Borsi, B. Carnemolla, and L. Zardi Use of Uteroglobin for the Engineering of Polyvalent, Polyspecific Fusion Proteins J. Biol. Chem., September 25, 2009; 284(39): 26646 - 26654. [Abstract] [Full Text] [PDF] C. Roesli, B. Borgia, C. Schliemann, M. Gunthert, H. Wunderli-Allenspach, R. Giavazzi, and D. Neri Comparative Analysis of the Membrane Proteome of Closely Related Metastatic and Nonmetastatic Tumor Cells Cancer Res., July 1, 2009; 69(13): 5406 - 5414. [Abstract] [Full Text] [PDF] N. Fowler and A. Younes There will be blood: targeting tumor vasculature Blood, March 5, 2009; 113(10): 2121 - 2122. [Full Text] [PDF] C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, E. Trachsel, W. Klapper, H. D. Menssen, and D. Neri Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood, March 5, 2009; 113(10): 2275 - 2283. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020